The PPARα ligand fenofibrate: Meeting multiple targets in diabetic nephropathy

Kidney International

Volumn 69, Issue 9, 2006, Pages 1490-1491

  Varghese, Z ^a   Moorhead, J F ^a   Ruan, X Z ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BEZAFIBRATE; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; ROSIGLITAZONE; TROGLITAZONE; ANTILIPEMIC AGENT; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY INJURY; LIPID MEDIATED KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; STEROL METABOLISM; ANIMAL; DRUG POTENTIATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

ANIMALS; ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; LIGANDS; MICE; PPAR ALPHA; PROCETOFEN;

EID: 33646521525     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000180     Document Type: Note

References (10)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30.
3. Zheng F, Fornoni A, Elliot SJ et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002; 282: F639-F648.
4. Baylis C, Atzpodien EA, Freshour G et al. Peroxisome proliferator- activated receptor gamma agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003; 307: 854-860.
5. Guan Y, Hao C, Cha DR et a/. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866.
6. Park CW, Zhang, Y, Zhang, X et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511-1517.
7. Ruan XZ, Moorhead JF, Fernando R et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 2003; 14: 593-600.
8. Mishra R, Emancipator SN, Miller C et al. Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney. Am J Physiol Renal Physiol 2004; 286: F913-F921.
9. Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002; 61: 1365-1376.
10. Ishizuka T, Ito O, Tan L et al. Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertens Res 2003; 26: 929-936.